长非编码RNA ZMIZ1‐AS1通过与hnRNPA1结合促进吉非替尼耐药性

IF 0.4 Q4 MEDICINE, RESEARCH & EXPERIMENTAL Precision Medical Sciences Pub Date : 2021-09-01 DOI:10.1002/prm2.12051
Changwen Jing, H. Cao, Jianzhong Wu, Rong Ma, Junying Zhang, Siwen Liu, Zhuo Wang
{"title":"长非编码RNA ZMIZ1‐AS1通过与hnRNPA1结合促进吉非替尼耐药性","authors":"Changwen Jing, H. Cao, Jianzhong Wu, Rong Ma, Junying Zhang, Siwen Liu, Zhuo Wang","doi":"10.1002/prm2.12051","DOIUrl":null,"url":null,"abstract":"To gain an insight into the molecular mechanisms of gefitinib resistance in nonsmall cell lung cancer, we screened out the long noncoding RNA related to gefitinib resistance through microarray data in gefitinib‐sensitive and resistant cells. lncRNA ZMIZ1‐AS1 was significantly upregulated in HCC827/GR cells by screening the microarray data. Further real‐time‐qPCR results were consistent with the microarray data. Cell viability assay and flow cytometry showed that ZMIZ1‐AS1 influenced the sensitivity of HCC827/GR cells to gefitinib. RNA pull‐down assay demonstrated that hnRNPA1 was a specific binding protein for ZMIZ1‐AS1. Our results help to reveal the role and mechanism of lncRNA in the secondary resistance of gefitinib and provide a new therapeutic target for gefitinib therapy.","PeriodicalId":40071,"journal":{"name":"Precision Medical Sciences","volume":"10 1","pages":"133 - 137"},"PeriodicalIF":0.4000,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/prm2.12051","citationCount":"0","resultStr":"{\"title\":\"Long noncoding RNA ZMIZ1‐AS1 promotes gefitinib resistance via binding to hnRNPA1\",\"authors\":\"Changwen Jing, H. Cao, Jianzhong Wu, Rong Ma, Junying Zhang, Siwen Liu, Zhuo Wang\",\"doi\":\"10.1002/prm2.12051\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"To gain an insight into the molecular mechanisms of gefitinib resistance in nonsmall cell lung cancer, we screened out the long noncoding RNA related to gefitinib resistance through microarray data in gefitinib‐sensitive and resistant cells. lncRNA ZMIZ1‐AS1 was significantly upregulated in HCC827/GR cells by screening the microarray data. Further real‐time‐qPCR results were consistent with the microarray data. Cell viability assay and flow cytometry showed that ZMIZ1‐AS1 influenced the sensitivity of HCC827/GR cells to gefitinib. RNA pull‐down assay demonstrated that hnRNPA1 was a specific binding protein for ZMIZ1‐AS1. Our results help to reveal the role and mechanism of lncRNA in the secondary resistance of gefitinib and provide a new therapeutic target for gefitinib therapy.\",\"PeriodicalId\":40071,\"journal\":{\"name\":\"Precision Medical Sciences\",\"volume\":\"10 1\",\"pages\":\"133 - 137\"},\"PeriodicalIF\":0.4000,\"publicationDate\":\"2021-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1002/prm2.12051\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Precision Medical Sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1002/prm2.12051\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Precision Medical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/prm2.12051","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

摘要

为了深入了解吉非替尼耐药在非小细胞肺癌中的分子机制,我们通过吉非替尼敏感和耐药细胞的微阵列数据筛选出与吉非替尼耐药相关的长链非编码RNA。通过筛选微阵列数据,lncRNA ZMIZ1‐AS1在HCC827/GR细胞中显著上调。进一步的实时qPCR结果与微阵列数据一致。细胞活力测定和流式细胞术显示ZMIZ1‐AS1影响HCC827/GR细胞对吉非替尼的敏感性。RNA拉下实验表明hnRNPA1是ZMIZ1‐AS1的特异性结合蛋白。我们的研究结果有助于揭示lncRNA在吉非替尼二次耐药中的作用和机制,为吉非替尼治疗提供新的治疗靶点。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Long noncoding RNA ZMIZ1‐AS1 promotes gefitinib resistance via binding to hnRNPA1
To gain an insight into the molecular mechanisms of gefitinib resistance in nonsmall cell lung cancer, we screened out the long noncoding RNA related to gefitinib resistance through microarray data in gefitinib‐sensitive and resistant cells. lncRNA ZMIZ1‐AS1 was significantly upregulated in HCC827/GR cells by screening the microarray data. Further real‐time‐qPCR results were consistent with the microarray data. Cell viability assay and flow cytometry showed that ZMIZ1‐AS1 influenced the sensitivity of HCC827/GR cells to gefitinib. RNA pull‐down assay demonstrated that hnRNPA1 was a specific binding protein for ZMIZ1‐AS1. Our results help to reveal the role and mechanism of lncRNA in the secondary resistance of gefitinib and provide a new therapeutic target for gefitinib therapy.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Precision Medical Sciences
Precision Medical Sciences MEDICINE, RESEARCH & EXPERIMENTAL-
自引率
0.00%
发文量
33
审稿时长
15 weeks
期刊最新文献
Prostatectomy postoperative urinary incontinence: From origin to treatment A case report of adult type 2 familial hemophagocytic lymphohistiocytosis Which inflammatory marker might be the best indicator for sacroiliitis? miRNAs involvement in the etiology and targeted therapy of bladder cancer: Interaction between signaling pathway Xiaotan Sanjie Fang prevents colonic inflammation‐related tumorigenesis by inhibiting COX‐2/VEGF expression cancer
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1